Outcome of Board Meeting

TORRENI PHARMA 30th July, 2026 The Dy. General Manager (Listing Dept.) The Manager – Listing Dept., BSE Limited, National Stock Exchange of India Ltd., Corporate Relationship Dept., Exchange Plaza, 5th Floor, 1st Floor, New Trading Ring, Plot No. C/1, G. Block, P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub.: Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) We would like to inform that the Board has at its meeting held today approved, inter alia, the Unaudited Standalone and Consolidated Financial Results along with limited review report of the Company for the quarter ended 30th June, 2026. The said financial results are enclosed herewith as an Annexure A. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter ended 30th June, 2026. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com A Press Release on Financial Results which is being submitted to the media is also enclosed herewith as an Annexure B. We would further like to inform that Ameera Shah (DIN: 00208095) will be completing her term as an Independent Director of the Company on 01st August, 2026. The Board meeting commenced at 02:00 pm and concluded at 04:40 pm. The above is for your information and record. TORRENT PHARMACEUTICALS LIMITED CIN L24230GJ1972PLC002126 Regd. Office, Avirat. Thaltej Shilaj Road, Ahmedabad -380059 Phone, +9179 26599000, Fax, +9179 26582100, www.torrentpharma.com Email – investorservices@torrentpharma.com TORRENI PHARMA Thanking you, Yours Sincerely, For TORRENT PHARMACEUTICALS LIMITED CHINTAN M. TRIVEDI COMPANY SECRETARY Encl: A/a TORRENT PHARMACEUTICALS LIMITED CIN L24230GJ1972PLC002126 Regd. Office Avirat, Thaltej Shilaj Road, Ahmedabad -380059 Phone: +91 79 26599000, Fax: +91 79 26582100, www.torrentpharma.com Email – investorservices@torrentpharma.com Annexure A 14th Floor, Central B Wing and North C Wing BS R & Co. LLP Nesco IT Park 4, Nesco Center Western Express Highway Chartered Accountants Goregaon (East), Mumbai - 400 063, India Telephone: +91 (22) 6257 1000 Fax: +91 (22) 6257 1010 Limited Review Report on unaudited standalone financial results of Torrent Pharmaceuticals Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended To the Board of Directors of Torrent Pharmaceuticals Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Torrent Pharmaceuticals Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement") (in which are included the standalone financial information of erstwhile J. B. Chemicals & Pharmaceuticals Limited (JBCPL). pursuant to the Scheme of Arrangement in the nature of Amalgamation of JBCPL with the Company which has been approved by the National Company Law Tribunal vide its order dated 06 July 2026 with the appointed date of 21 January 2026). 2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended. Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statem'ent in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. We draw attention to Note 4 to the accompanying standalone financial results, which describes the Scheme of Amalgamation (Scheme) of JBCPL with the Company, approved by the Honourable National Company Law Tribunal ("NCL T") vide its Order dated 6 July 2026 and a certified copy has been filed by the Company with the Registrar of Companies, Ahmedabad on 8 July 2026. In accordance with the scheme approved by NCL T, the amalgamation has been accounted for in the quarter ended 30 June 2026 with effect from the appointed date of 21 January 2026, and accordingly, the comparative financial information for the quarter and year ended 31 March 2026 has been restated. / j? _9.ur conclusion is not modified in respect of this matter. ~ Registered Office· BS R & Co. {a partnership firm wilh Registra!ion No. BA61223) converted Into BS R & Co. LLP (a 14th Floor, Central B Wing and North C \/\ling, Nesco IT Park 4, Nesco Limited liability Partnership \..,.;th LLP Registration No. AAB-6181) with effect from October 14, 2013 Center, Western Express Highway, Goregaon (East), Mumbai-400063 Page 1 of 2 BS R & Co. LLP Limited Review Report (Continued) Torrent Pharmaceuticals Limited 6. The corresponding amounts for the quarter and year ended 31 March 2026, includes financial results of JBCPL (considered pursuant to the Scheme of Amalgamation of JBCPL with the Company as stated in Note 4), whose financial results reflect total assets of Rs. 4,823.50 crores as at 31 March 2026, total revenue of Rs. 712.74 crores, total net profit after tax Rs. 133.97 crores and total comprehensive income of Rs. 136.45 crores, for the period from 21 January 2026 to 31 March 2026. These financial results of JBCPL has been audited by other auditor who had expressed an unmodified opinion and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of JBCPL, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of this matter. 7. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2026 as reported [Showing first 8,000 characters — download PDF for full document]